Dr. Gary Striker is a Professor of Medicine at Mount Sinai, and Professor of Medicine and Surgery at the University of Miami School of Medicine in Miami, Florida. He maintains research laboratories devoted to stem cells, aging and diabetes-related topics in both New York, New York, and Miami, Florida.
After receiving his medical degree from the University of Washington School of Medicine in Seattle, he completed his Rotating Internship in General Medicine at the University Hospital in Seattle. He then completed a Residency in Pathology at University of California at Los Angeles-Wadsworth General Hospital and the Veterans Administration Medical Center in Los Angeles. He returned to the University of Washington-Seattle for his Fellowship in Experimental Pathology. He is board certified in Anatomic Pathology and Clinical Pathology, and is licensed to practice in California, Washington, Maryland, and Florida.
His academic career began at the University of Washington, where he became a Professor in 1972. He directed the M.D.-Ph.D. program and was the Dean for Curriculum, among many other activities at the University of Washington. He became Director of the Kidney, Urology, and Hematology Division, NIDDK, NIH in 1984 until 1997. He was Director of the Vascular Biology Institute at the University of Miami from 1997-2004. He came to Mount Sinai School of Medicine in 2004, where he is Professor of Medicine in the Division of Nephrology.
He has been an NIH-funded investigator since the late 1960s.
Adler SG, Kang SW, Feld S, Cha DR, Barba L, Striker LJ, Striker GE, Riser BL, Lapage J, Nast CC. Glomerular mRNAs in human type 1 diabetes: biochemical evidence for microalbuminuria as a manifestation of diabetic nephropathy. Kidney Int 2001 Dec; 60(6): 2330-6.
Fornoni A, Striker LJ, Zheng F, Striker G. Reversibility of glucose-induced changes in mesangial cell extracellular matrix depends on the genetic background. Diabetes 2002 Feb; 51(2): 499-505.
Fornoni A, Wang Y, Lenz O, Striker LJ, Striker GE. Association of a decreased number of d(CA) repeats in the matrix metalloproteinase-9 promoter with glomerulosclerosis susceptibility in mice. J Am Soc Nephrol 2002 Aug; 13(8): 2068-76.
Zheng F, Plati AR, Banerjee A, Elliot S, Striker LJ, Striker GE. The molecular basis of age-related kidney disease. Sci Aging Knowledge Environ 2003 Jul 23; 2003(29): PE20.
Fornoni A, Lenz O, Striker LJ, Striker GE. Glucose induces clonal selection and reversible dinucleotide repeat expansion in mesangial cells isolated from glomerulosclerosis-prone mice. Diabetes 2003 Oct; 52(10): 2594-602.
Potier M, Karl M, Elliot SJ, Striker GE, Striker LJ. Response to sex hormones differs in atherosclerosis-susceptible and -resistant mice. Am J Physiol Endocrinol Metab 2003 Dec; 285(6): E1237-45.
Zheng F, Plati AR, Potier M, Schulman Y, Berho M, Banerjee A, Leclercq B, Zisman A, Striker LJ, Striker GE. Resistance to glomerulosclerosis in B6 mice disappears after menopause. Am J Pathol 2003 Apr; 162(4): 1339-48.
Zheng F, Cornacchia F, Schulman I, Banerjee A, Cheng QL, Potier M, Plati AR, Berho M, Elliot SJ, Li J, Fornoni A, Zhang YJ, Zisman A, Striker LJ, Striker GE. Development of albuminuria and glomerular lesions in normoglycemic B6 recipients of db/db mice bone marrow: the role of mesangial cell progenitors. Diabetes 2004 Sep; 53(9): 2420-7.
Zheng F, Cheng QL, Plati AR, Ye SQ, Berho M, Banerjee A, Potier M, Jaimes EA, Yu H, Guan YF, Hao CM, Striker LJ, Striker GE. The glomerulosclerosis of aging in females: contribution of the proinflammatory mesangial cell phenotype to macrophage infiltration. Am J Pathol 2004 Nov; 165(5): 1789-98.
Feng Z, Plati AR, Cheng QL, Berho M, Banerjee A, Potier M, Jy WC, Koff A, Striker LJ, Striker GE. Glomerular aging in females is a multi-stage reversible process mediated by phenotypic changes in progenitors. Am J Pathol 2005 Aug; 167(2): 355-63.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Striker did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.